Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
AT0000785555
Thu, 26.09.2024
Semperit AG Holding
Semperit: Manfred Stanek appointed new CEO
Vienna, 26 September 2024 – The Supervisory Board of Semperit AG Holding appointed Manfred Stanek as the new CEO of Semperit AG Holding today. He will join the Executive Board on 1March 2025 and take over the role of CEO on 1 April 2025; his mandate as a member of the Executive Board will run until 29 Fe [ … ]
Tue, 13.08.2024
Semperit AG Holding
Semperit increases profitability in the first half of 2024
EBITDA up 8% to EUR 47.3 million, earnings after tax more than doubled
Free cash flow significantly improved to EUR 23.6 million
Cost-cutting program takes effect: cost reductions of EUR 14.4 million, of which EUR 8.6 million in H1
EBITDA guidance confirmed at around EUR 80 million f [ … ]
Mon, 01.07.2024
Semperit AG Holding
Semperit finalizes sale of the remaining medical business
Vienna, July 1, 2024 – Semperit has completed the sale of the medical business and transferred the remaining production and packaging of surgical gloves to the buyer of the entire medical business, the Southeast Asian Harps Global, as agreed. Combined under the discontinued operations “Surg [ … ]
Mon, 10.06.2024
Semperit AG Holding
Semperit: Executive Board Chairman Karl Haider will not extend his contract
Vienna, June 10, 2024 – Karl Haider today informed the Chairman of the Supervisory Board of Semperit AG Holding that he will not be available for an extension of his Executive Board mandate, which expires on March 31, 2025. Karl Haider, who was appointed to the Executive B [ … ]
Wed, 15.05.2024
Semperit AG Holding
Semperit with stable revenue and 9% EBITDA increase in Q1 2024
Continued operations with revenue of EUR 176.0 million (–0.2%) and EBITDA of EUR 23.0 million (+9.4%)
Cost reductions initiated in the previous year already reduced expenses by EUR 9.9 million, of which EUR 4.1 million was attributable to Q1 2024
EBITDA guidance of around EUR 80 [ … ]
Tue, 19.03.2024
Semperit AG Holding
Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business
Continued operations with revenue of EUR 721.1 million (–7.5%), EBITDA of EUR 71.8 million (–28.5%) and positive earnings after tax of EUR 24.9 million (–35.2%)
Cost reductions with a run rate of more than EUR 10 million p [ … ]
Thu, 25.01.2024
Semperit AG Holding
Semperit starts its 200th anniversary year
Vienna, 25 January 2024 – The Semperit Group is celebrating its 200th anniversary in 2024. Founded in 1824, the company is taking this anniversary as an opportunity to highlight its centuries-long tradition but also its path to a successful future in a variety of ways under the motto “200 Years of Semper [ … ]
Wed, 08.11.2023
Semperit AG Holding
Semperit holds its ground in a difficult market environment and has completed its repositioning as an elastomers specialist
As expected, revenue in continued operations of EUR 547.6 million (–7.7%) and EBITDA of EUR 56.8 million (–28.8%) below the previous year’s level
Cost reductions with a run rate of more than EUR 10 million being implemented, [ … ]
Wed, 25.10.2023
Semperit AG Holding
Semperit again with top ESG rating by EcoVadis
Platinum award for the second year in a row
Semperit among the top 1% worldwide for quality of sustainability management
Participation in WU study on supply chain responsibility
Vienna, 25 October 2023 – For the second time, the Semperit Group has received the highest platinum award in the EcoVadi [ … ]
Thu, 31.08.2023
Semperit AG Holding
Semperit successfully completes sale of medical business and focuses on growth in industrial core business
Transformation into industrial rubber/elastomer specialist implemented
Payment of additional dividend of EUR 3.00 per share on 14 September 2023
Vienna, 31 August 2023 – The Semperit Group has successfully completed the sale of its med [ … ]